Home >Research Discovery>Discovery Biology

Tuberculosis Lab

Introduction of group leader

Vincent Delorme, Ph.D.
Doctorate: Aix-Marseille University, France (2012)
Post-doctorate: National Institute for Health and Medicinal Research (INSERM), France (2012-2015)
Head, Tuberculosis Research Laboratory, Institute Pasteur Korea (2015-present)

Office phone: +82-31-8018-8190
Email: vincent.delorme at ip-korea.org
Office location: R4.35

Research Interests

Our laboratory is focused on understanding the basic biology of Mycobacterium tuberculosis, the bacterium responsible for tuberculosis (TB) in humans, and discovering novel molecular entities that can be used in the treatment of the disease. TB is one of the most infectious diseases in the world, killing around 1.5 million people per year, and is a threat to public health. The emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) TB, is exerting pressure to develop new strategies for addressing the disease as we are running out of effective treatment options.

Using unique cell-based phenotypic screening technology platform for drug discovery, the laboratory discovered Q203, a novel, first-in-class clinical candidate for TB treatment highly effective against both MDR and XDR TB. Q203 is currently in clinical trials in the U.S. and was designated as an Orphan Drug by the FDA (as of Aug 2016).

The Tuberculosis Research Laboratory focuses on:

• Developing cellular infection models to study host-pathogen interactions during latency,
• Investigating drug mechanism of action to highlight relevant bacterial weaknesses,
• Carrying out drug screening campaigns in order to discover new chemicals of interest to fight TB,
• Exploring alternative libraries like natural products to discover new targets and innovative pathways against this disease,
• Selecting the most promising molecules for drug development by testing their efficacy in animal models.
 

Recent Publications

Mycobacterium tuberculosis Infection and Innate Responses in a New Model of Lung Alveolar Macrophages.
Woo M, Wood C, Kwon D, Park KP, Fejer G, Delorme V
Front Immunol. 2018 Mar 12;9:438

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
Blondiaux N, Moune M, Desroses M, Frita R, Flipo M, Mathys V, Soetaert K, Kiass M, Delorme V, Djaout K, Trebosc V, Kemmer C, Wintjens R, Wohlkonig A, Antoine R, Huot L, Hot D, Coscolla M, Feldmann J, Gagneux S, Locht C, Brodin P, Gitzinger M, Deprez B, Willand N, Baulard AR
Science. 2017 Mar 17;355(6330):1206-1211

Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis. Jang J, Kim R, Woo M, Jeong J, Park DE, Kim G, Delorme V
Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02637-16

High-Content Screening of Raw Actinomycete Extracts for the Identification of Antituberculosis Activities.
Heo J, Nam J, Jang J, Shum D, Radu C, Cheng J, Lee H, Suh JW, Delorme V
SLAS Discov. 2017 Feb;22(2):144-154

A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening.
Queval CJ*, Song OR*, Delorme V*, Iantomasi R, Veyron-Churlet R, Deboosère N, Landry V, Baulard A, Brodin P
J Vis Exp. 2014 Jan 17;(83):e51114